Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 17, 2024, regarding events occurring on May 16, 2024. Vivos Therapeutics, Inc., a Delaware corporation listed on The Nasdaq Capital Market, is reporting a material development concerning its continued listing status.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or cash flow figures. The primary financial metric disclosed is the Company's stockholders' equity. According to the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2024, stockholders' equity was reported as less than $2.5 million, which is the minimum threshold required by Nasdaq Listing Rule 5550(b)(1).
Material Changes and Listing Status
- Previous Compliance: The Company previously reported on May 3, 2024, that it had regained compliance with the $2.5 million Minimum Stockholders' Equity Requirement as of March 19, 2024, following capital raising activities in November 2023 and February 2024. Nasdaq staff confirmed this compliance on May 6, 2024.
- Current Non-Compliance: On May 16, 2024, Nasdaq staff issued a new notice determining that the Company had failed to meet the Minimum Stockholders' Equity Requirement as of the date of the notice, citing the equity levels reported in the March 31, 2024, 10-Q.
- Delisting Proceedings: Nasdaq indicated it would commence delisting proceedings against the Company based on this determination.
Outlook, Risks, and Management Commentary
The Company has filed an appeal with the Nasdaq Hearing Panel to request an additional hearing. This appeal has stayed any immediate delisting or suspension action, and the Company's common stock will remain listed pending the Hearing Panel's decision. Management is undertaking efforts to regain and evidence continuing compliance with the equity requirement.
Risks and Contingencies:
- There is a risk the Company will be unable to demonstrate compliance to the Hearing Panel.
- Even if the Company believes it has regained compliance, there is no assurance the Hearing Panel will grant continued listing.
- If delisted, the Company faces a material adverse effect on its stock price, stockholder liquidity, ability to raise capital, and reputation.
Key Facts for Investor Verification
- Verify the current status of the appeal before the Nasdaq Hearing Panel and the expected timeline for a decision.
- Review the specific stockholders' equity figure from the Form 10-Q for the period ended March 31, 2024, to understand the magnitude of the shortfall.
- Monitor for any new capital raising activities or financial updates the Company may disclose to address the equity deficiency.
- Assess the potential impact of a delisting on the liquidity and trading venue of VVOS shares.